Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?

Parnetti L, Mignini F, Tomassoni D, Traini E, Amenta F.

J Neurol Sci. 2007 Jun 15;257(1-2):264-9. Epub 2007 Feb 28. Review.

PMID:
17331541
2.
3.
4.
5.

CDP-choline: pharmacological and clinical review.

Secades JJ, Frontera G.

Methods Find Exp Clin Pharmacol. 1995 Oct;17 Suppl B:1-54. Review.

PMID:
8709678
6.

The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies.

Amenta F, Di Tullio MA, Tomassoni D.

Clin Exp Hypertens. 2002 Oct-Nov;24(7-8):697-713. Review.

PMID:
12450245
7.
8.

Citicoline: pharmacological and clinical review, 2006 update.

Secades JJ, Lorenzo JL.

Methods Find Exp Clin Pharmacol. 2006 Sep;28 Suppl B:1-56. Review.

PMID:
17171187
9.
10.

Effect of choline-containing phospholipids on brain cholinergic transporters in the rat.

Tayebati SK, Tomassoni D, Di Stefano A, Sozio P, Cerasa LS, Amenta F.

J Neurol Sci. 2011 Mar 15;302(1-2):49-57. doi: 10.1016/j.jns.2010.11.028. Epub 2010 Dec 31.

PMID:
21195433
11.

Investigational treatment for vascular cognitive impairment.

Birks J, Flicker L.

Expert Opin Investig Drugs. 2007 May;16(5):647-58. Review.

PMID:
17461738
12.
13.

Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which?

Lockhart BP, Lestage PJ.

Exp Gerontol. 2003 Jan-Feb;38(1-2):119-28. Review.

PMID:
12543269
14.

[Pharmacological treatment of vascular cognitive impairment].

Bidzan L.

Przegl Lek. 2006;63(3):131-3. Review. Polish.

PMID:
16969897
15.

Therapeutic issues in vascular dementia: studies, designs and approaches.

Black SE.

Can J Neurol Sci. 2007 Mar;34 Suppl 1:S125-30. Review.

PMID:
17474183
16.

Revisiting choline alphoscerate profile: a new, perspective, role in dementia?

Scapicchio PL.

Int J Neurosci. 2013 Jul;123(7):444-9. doi: 10.3109/00207454.2013.765870. Epub 2013 Feb 19. Review.

PMID:
23387341
17.

Citicoline, use in cognitive decline: vascular and degenerative.

García-Cobos R, Frank-García A, Gutiérrez-Fernández M, Díez-Tejedor E.

J Neurol Sci. 2010 Dec 15;299(1-2):188-92. doi: 10.1016/j.jns.2010.08.027. Epub 2010 Sep 27. Review.

PMID:
20875651
18.

Modulation of monoaminergic transporters by choline-containing phospholipids in rat brain.

Tayebati SK, Tomassoni D, Nwankwo IE, Di Stefano A, Sozio P, Cerasa LS, Amenta F.

CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):94-103.

PMID:
23244432
19.

Current concepts in vascular cognitive impairment and pharmacotherapeutic implications.

Rojas-Fernandez CH, Moorhouse P.

Ann Pharmacother. 2009 Jul;43(7):1310-23. doi: 10.1345/aph.1L703. Epub 2009 Jul 7. Review.

PMID:
19584390
20.

Citicoline in vascular cognitive impairment and vascular dementia after stroke.

Alvarez-Sabín J, Román GC.

Stroke. 2011 Jan;42(1 Suppl):S40-3. doi: 10.1161/STROKEAHA.110.606509. Epub 2010 Dec 16. Review.

Supplemental Content

Support Center